Core Viewpoint - The report from CITIC Securities indicates that Haijia Medical (06078) will experience a phase of performance pressure in H1 2025, but high-quality development is beginning to show results [1] Group 1: Company Performance - The proportion of technical services in the company's operations continues to increase [1] - The construction of the talent team is being actively promoted [1] - New projects are progressing in an orderly manner [1] Group 2: Future Outlook - The company is continuously developing innovative medical services [1] - Based on comparable company valuation levels, a 20x PE is assigned for the year 2025, leading to a target price of 20 HKD [1] - The "Buy" rating is maintained for the company [1]